Books
in black and white
Main menu
Share a book About us Home
Books
Biology Business Chemistry Computers Culture Economics Fiction Games Guide History Management Mathematical Medicine Mental Fitnes Physics Psychology Scince Sport Technics
Ads

biopharmaceuticals biochemistry and biotecnology - Walsh G.

Walsh G. biopharmaceuticals biochemistry and biotecnology - John Wiley & Sons, 2003. - 572 p.
ISBN 0-470-84327-6
Download (direct link): biochemistryandbiotechnology2003.pdf
Previous << 1 .. 243 244 245 246 247 248 < 249 > 250 251 252 253 254 255 .. 292 >> Next

Chapman, P. (2002). PEGylated antibodies and antibody fragments for improved therapy: a review. Adv. Drug Deliv. Rev. 54(4), 531-545.
Chester, K. & Hawkins, R. (1995). Clinical issues in antibody design. Trends Biotechnol. 13, 294-300.
Funaro, A. et al. (2000). Monoclonal antibodies and the therapy of human cancers. Biotechnol. Adv. 18(5), 385-401. Goldenberg, D. et al. (2002). Targeted therapy of cancer with radiolabeled antibodies. J. Nuclear Med. 43(5), 693-713. Hoogenboom, H. et al. (1998). Antibody phage display technology and its applications. Immunotechnology 4, 1-20. Huennekens, F. (1994). Tumor targeting: activation of prodrugs by enzyme-monoclonal antibody conjugates. Trends Biotechnol. 12, 234-239.
Keating, G. & Perry, C. (2002). Infliximab — an updated review of its use in Crohn’s disease and rheumatoid arthritis. Biodrugs 16(2), 111-148.
Kohler, G. & Milstein, C. (1975). Continuous culture of fused cells secreting antibody of pre-defined specificity. Nature 256, 495-497.
Murry, J. (2000). Monoclonal antibody treatment of solid tumors: a coming of age. Semin. Oncol. 27(6), 64-70. Senter, P. & Springer, C. (2001). Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates. Adv. Drug Deliv. Rev. 53(3), 247-264.
Trail, P. & Bianchi, A. (1999). Monoclonal antibody drug conjugates in the treatment of cancer. Curr. Opin. Immunol. 11(5), 584-588.
Umemura, S. et al. (2002). Pathological evaluation of HER2 overexpression for the treatment of metastatic breast cancers by humanized anti-HER2 monoclonal antibody (Trastuzumab). Acta Biochim. Cytochim. 35(2), 77-81. Wang, R. (1999). Human tumor antigens: implications for cancer vaccine development. J. Mol. Med. 77(9), 640-655. Wang, R. & Rosenberg, S. (1999). Human tumor antigens for cancer vaccine development. Immunol. Rev. 170, 85-100. Winter, G. & Milstein, C. (1991). Man-made antibodies. Nature 349, 293-299.
Vaccine technology
Andino, R. et al. (1994). Engineering poliovirus as a vaccine vector for the expression of diverse antigens. Science 265, 1448-1451.
Chauhan, V. (1996). Progress towards malaria vaccine. Curr. Sci. 71(12), 967-975.
Cox, J. & Coutter, A. (1997). Adjuvants — a classification and review of their modes of action. Vaccine 15(3), 248-256. Doolan, D. & Hoffman, S. (1997). Multigene vaccination against malaria — a multistage, multi-immune response approach. Parasitol. Today 13(5), 171-178.
ANTIBODIES, VACCINES AND ADJUVANTS 461
Edelman, R. (2002). The development and use of vaccine adjuvants. Mol. Biotechnol. 21(2), 129-148.
Esparza, J. et al. (1995). HIV-preventive vaccines, progress to date. Drugs 50(5), 792-804.
Frontiers in Medicine: Vaccines (1994). Science 265 (Special Issue, September 2).
Gaschen, B. et al. (2002). AIDS — diversity considerations in HIV-1 vaccine selection. Science 296(5577), 2354-2360.
Gupta, R. & Siber, G. (1995). Adjuvants for human vaccines — current status, problems and future prospects. Vaccine 13(14), 1263-1274.
Hilton, L. et al. (2002). The emerging role of avian cytokines as immunotherapeutics and vaccine adjuvants. Vet. Immunol. Immunopathol. 85(3-4), 119-128.
Lachman, L. et al. (1996). Cytokine-containing liposomes as vaccine adjuvants. Eur. Cytokine Network 7(4), 693-698.
Lemon, S. & Thomas, D. (1997). Drug therapy — vaccines to prevent viral hepatitis. N. Engl. J. Med. 336(3), 196-204.
Mason, H. et al. (2002). Edible plant vaccines: applications for prophylactic and therapeutic molecular medicine. Trends Mol. Med. 8(7), 324-329.
Ohagan, D. et al. (1997). Recent advances in vaccine adjuvants — the development of Mf59 emulsion and polymeric microparticles. Mol. Med. Today 3(2), 69-75.
Perkus, M. et al. (1995). Poxvirus-based vaccine candidates for cancer, AIDS and other infectious diseases. J. Leukocyte Biol. 58, 1-10.
Plotkin, S. (2002). Vaccines in the twenty-first century. Hybridoma Hybridom. 21(2), 135-145.
Poland, G. et al. (2002). Science, medicine and the future — new vaccine development. Br. Med. J. 324(7349), 1315-1319.
Russo, S. et al. (1997). What’s going on in vaccine technology? Med. Res. Rev. 17(3), 277-301.
Sandhu, J. (1994). Engineered human vaccines. Crit. Rev. Biotechnol. 14(1), 1-27.
Sela, M. et al. (2002). Therapeutic vaccines: realities of today and hopes for the future. Drug Discovery Today 7(12), 664-673.
Singh, M. & O’Hagan, D. (2002). Recent advances in vaccine adjuvants. Pharmaceut. Res. 19(6), 715-728.
Strominger, J. (1995). Peptide vaccination against cancer? Nature Med. 1(11), 1140.
Wang, R. & Rosenberg, S. (1999). Human tumor antigens for cancer vaccine development. Immun. Rev. 170, 85-100.
Yokoyama, N. et al. (1997). Recombinant viral vector vaccines for veterinary use. J. Vet. Med. Sci. 59(5), 311-322.
Chapter 11 Nucleic acid therapeutics
Throughout the 1980s and early 1990s, the term ‘biopharmaceutical’ had become virtually synonymous with ‘proteins of therapeutic use’ (Chapter 1). Nucleic acid-based biopharmaceuticals, however, harbour great potential — a potential which is likely to become a medical reality within this decade. Current developments in nucleic acid based-therapeutics centre around gene therapy and antisense technology. These technologies have the potential to revolutionize medical practice. Their full benefit, however, will accrue only after the satisfactory resolution of several technical difficulties currently impeding their routine medical application.
Previous << 1 .. 243 244 245 246 247 248 < 249 > 250 251 252 253 254 255 .. 292 >> Next